Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56 Case report
Article Sidebar
Published:
Apr 1, 2023
Keywords:
non-metastatic castration-resistant prostate cancer, apalutamide, androgen receptor inhibitor
Main Article Content
Abstract
The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Trzebiński K. Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56. OncoReview [Internet]. 2023Apr.1 [cited 2024Dec.22];13(1(49):27-0. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/2791
Issue
Section
SUPPORTIVE CARE IN ONCOLOGY
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49. http://doi.org/10.3322/caac.21660.
2. Didkowska J, Wojciechowska U, Olasek P et al. Nowotwory złośliwe w Polsce w 2019 roku. Warszawa 2021.
3. Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378: 1408-18. http://doi.org/10.1056/NEJMoa1715546.
4. Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31: 1119-34. http://doi.org/10.1016/j.annonc.2020.06.011.
5. Howard LE, Moreira DM, De Hoedt A et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017; 120(5B): E80-6. http://doi.org/10.1111/bju.13856.
2. Didkowska J, Wojciechowska U, Olasek P et al. Nowotwory złośliwe w Polsce w 2019 roku. Warszawa 2021.
3. Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378: 1408-18. http://doi.org/10.1056/NEJMoa1715546.
4. Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31: 1119-34. http://doi.org/10.1016/j.annonc.2020.06.011.
5. Howard LE, Moreira DM, De Hoedt A et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017; 120(5B): E80-6. http://doi.org/10.1111/bju.13856.